New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
By C. Devaux, J. Rolain, P. Colson, Didier Raoult. International Journal of Antimicrobial Agents, 2020
1,019 citations recorded by the source corpus.
Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/b1a499a98dd82d0ef47851f42b314dc02e4c1da8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. P. Ambhore
- S. Shinde
- R. Narkhede
- R. Cheke
Citations in the corpus
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “(%) ICU: 13 (32); ARDS: 12 (29); MI: 5 (12); AKI: 3 (7); shock: 3 (7); secondary infection: 4 (10) ICU: 23 (23); ARDS: 17 (17); AKI: 3 (3); shock: 4 (4); VAP: 1 (1) ICU: 36 (26); ARDS: 27 (20); MI: 10 (7.”
- The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2 (2020, background): “[16] At low pH, these drugs are also believed to interfere in post-translational modification in viral protease and glycosyl transferases in the endoplasmic reticulum or vesicles of the trans-Golgi complex.[16] Therefore, docking of chloroquine and hydroxychloroquine with the COVID-19 Mpro (in compl”